Bellus Health (BLUSF) could have its shares soon trading on the NASDAQ exchange. This is a very favourable announcement. As a result, we believe that market liquidity will increase, which may push the share price of Bellus up. We are positive on the stock. Another stock catalyst, which may enhance the company’s valuation, is the release of data from the Phase 2 clinical trial. However, notice that the study will most likely not be completed until April 30, 2020.
Source: Prospectus
Business Model And Clinical Results
With shares trading on the Toronto Stock